Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly will pay as much as $600 million to acquire Beam Therapeutics' opt-in rights on Verve Therapeutics' base editing cardiovascular programs. The deal…
Eli Lilly is spending up to $600 million to acquire Beam Therapeutics' opt-in rights to Verve Therapeutics' cardiovascular base editing programs. Under the…
VERVE-102 Heart-2 Phase 1b positive initial data: dose-dependent reductions in PCSK9 and LDL-C, mean LDL-C reduction 53% and max 69% at 0.6 mg/kg; no…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Lilly acquired Beam's opt-in rights to Verve Therapeutics' base editing cardiovascular programs (VERVE-101/102/201). Beam received $200M upfront and $50M equity investment, plus eligibility for up to $350M in development-stage payments, total deal up to $600M. UPDATE (post-deal developments): In 2024 Verve discontinued VERVE-101 after a grade-3 transient ALT elevation and serious thrombocytopenia in the Heart-1 Phase 1b trial, shifting its lead PCSK9 program to VERVE-102 (Heart-2), which uses the same base editor with a redesigned LNP. VERVE-102 reported positive initial Heart-2 data on April 14, 2025 (mean LDL-C reduction 53%, max 69% at 0.6 mg/kg; no treatment-related serious adverse events). Lilly then acquired Verve Therapeutics outright — announced June 17, 2025 and completed July 25, 2025 — for $10.50/share in cash plus a contingent value right of up to $3.00/share (total potential ~$1.3B). The 2025 acquisition consolidated the full Verve cardiovascular base-editing portfolio under Lilly, absorbing the assets to which this 2023 Beam transaction had granted only opt-in rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Beam Therapeutics Inc. (this deal) | 2023 | $600M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2023 deals · Eli Lilly and Company deals · Cardiovascular deals